230 related articles for article (PubMed ID: 28218273)
21. Discovery of novel drug candidates for inhibition of soluble epoxide hydrolase of arachidonic acid cascade pathway implicated in atherosclerosis.
Gurung AB; Mayengbam B; Bhattacharjee A
Comput Biol Chem; 2018 Jun; 74():1-11. PubMed ID: 29522918
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and structure-activity relationships for some novel diflapolin derivatives with benzimidazole subunit.
Vieider L; Zoeller E; Romp E; Schoenthaler M; Hernández-Olmos V; Temml V; Hasenoehrl T; Schuster D; Werz O; Garscha U; Matuszczak B
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1752-1764. PubMed ID: 36124840
[TBL] [Abstract][Full Text] [Related]
23. An experimental cell-based model for studying the cell biology and molecular pharmacology of 5-lipoxygenase-activating protein in leukotriene biosynthesis.
Gerstmeier J; Weinigel C; Barz D; Werz O; Garscha U
Biochim Biophys Acta; 2014 Sep; 1840(9):2961-9. PubMed ID: 24905297
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of Chronic Pancreatitis and Murine Pancreatic Intraepithelial Neoplasia by a Dual Inhibitor of c-RAF and Soluble Epoxide Hydrolase in LSL-KrasG¹²D/Pdx-1-Cre Mice.
Liao J; Hwang SH; Li H; Liu JY; Hammock BD; Yang GY
Anticancer Res; 2016 Jan; 36(1):27-37. PubMed ID: 26722025
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and structure-activity relationship of piperidine-derived non-urea soluble epoxide hydrolase inhibitors.
Pecic S; Pakhomova S; Newcomer ME; Morisseau C; Hammock BD; Zhu Z; Rinderspacher A; Deng SX
Bioorg Med Chem Lett; 2013 Jan; 23(2):417-21. PubMed ID: 23237835
[TBL] [Abstract][Full Text] [Related]
26. Structure-based drug design on membrane protein targets: human integral membrane protein 5-lipoxygenase-activating protein.
Ferguson AD
Methods Mol Biol; 2012; 841():267-90. PubMed ID: 22222457
[TBL] [Abstract][Full Text] [Related]
27. Ligand-based Modeling for the Prediction of Pharmacophore Features for Multi-targeted Inhibition of the Arachidonic Acid Cascade.
Saroj Devi N; Shanmugam R; Ghorai J; Ramanan M; Anbarasan P; Doble M
Mol Inform; 2018 Mar; 37(3):. PubMed ID: 28991413
[TBL] [Abstract][Full Text] [Related]
28. Targeting soluble epoxide hydrolase for inflammation and pain - an overview of pharmacology and the inhibitors.
Pillarisetti S; Khanna I
Inflamm Allergy Drug Targets; 2012 Apr; 11(2):143-58. PubMed ID: 22280237
[TBL] [Abstract][Full Text] [Related]
29. A Single Amino Acid Difference between Mouse and Human 5-Lipoxygenase Activating Protein (FLAP) Explains the Speciation and Differential Pharmacology of Novel FLAP Inhibitors.
Blevitt JM; Hack MD; Herman K; Chang L; Keith JM; Mirzadegan T; Rao NL; Lebsack AD; Milla ME
J Biol Chem; 2016 Jun; 291(24):12724-12731. PubMed ID: 27129215
[TBL] [Abstract][Full Text] [Related]
30. Synthesis of substituted fluorobenzimidazoles as inhibitors of 5-lipoxygenase and soluble epoxide hydrolase for anti-inflammatory activity.
Nandha B; Ramareddy SA; Kuntal H
Arch Pharm (Weinheim); 2018 Jun; 351(6):e1800030. PubMed ID: 29732612
[TBL] [Abstract][Full Text] [Related]
31. Discovery of a benzenesulfonamide-based dual inhibitor of microsomal prostaglandin E
Cheung SY; Werner M; Esposito L; Troisi F; Cantone V; Liening S; König S; Gerstmeier J; Koeberle A; Bilancia R; Rizza R; Rossi A; Roviezzo F; Temml V; Schuster D; Stuppner H; Schubert-Zsilavecz M; Werz O; Hanke T; Pace S
Eur J Med Chem; 2018 Aug; 156():815-830. PubMed ID: 30053720
[TBL] [Abstract][Full Text] [Related]
32. Discovery and Optimization of Piperazine Urea Derivatives as Soluble Epoxide Hydrolase (sEH) Inhibitors.
Çapan İ; Jordan PM; Olğaç A; Çalışkan B; Kretzer C; Werz O; Banoglu E
ChemMedChem; 2022 Jun; 17(12):e202200137. PubMed ID: 35466565
[TBL] [Abstract][Full Text] [Related]
33. Soluble epoxide hydrolase inhibitors: an overview and patent review from the last decade.
Iyer MR; Kundu B; Wood CM
Expert Opin Ther Pat; 2022 Jun; 32(6):629-647. PubMed ID: 35410559
[TBL] [Abstract][Full Text] [Related]
34. Identification of multi-target inhibitors of leukotriene and prostaglandin E
Gür ZT; Çalışkan B; Garscha U; Olgaç A; Schubert US; Gerstmeier J; Werz O; Banoglu E
Eur J Med Chem; 2018 Apr; 150():876-899. PubMed ID: 29597170
[TBL] [Abstract][Full Text] [Related]
35. Characterization of the interaction of human 5-lipoxygenase with its activating protein FLAP.
Häfner AK; Gerstmeier J; Hörnig M; George S; Ball AK; Schröder M; Garscha U; Werz O; Steinhilber D
Biochim Biophys Acta; 2015 Nov; 1851(11):1465-72. PubMed ID: 26327594
[TBL] [Abstract][Full Text] [Related]
36. Discovery of enantioselectivity of urea inhibitors of soluble epoxide hydrolase.
Manickam M; Pillaiyar T; Boggu P; Venkateswararao E; Jalani HB; Kim ND; Lee SK; Jeon JS; Kim SK; Jung SH
Eur J Med Chem; 2016 Jul; 117():113-24. PubMed ID: 27092411
[TBL] [Abstract][Full Text] [Related]
37. Hybrid Receptor-Bound/MM-GBSA-Per-residue Energy-Based Pharmacophore Modelling: Enhanced Approach for Identification of Selective LTA4H Inhibitors as Potential Anti-inflammatory Drugs.
Appiah-Kubi P; Soliman M
Cell Biochem Biophys; 2017 Mar; 75(1):35-48. PubMed ID: 27914004
[TBL] [Abstract][Full Text] [Related]
38. Screening of soluble epoxide hydrolase inhibitory ingredients from traditional Chinese medicines for anti-inflammatory use.
Liu JY; Morisseau C; Huang H; Hammock BD
J Ethnopharmacol; 2016 Dec; 194():475-482. PubMed ID: 27702689
[TBL] [Abstract][Full Text] [Related]
39. Novel amide derivatives of 3-phenylglutaric acid as potent soluble epoxide hydrolase inhibitors.
Rezaee E; Amrolah SM; Nazari M; Tabatabai SA
Mol Divers; 2021 Feb; 25(1):45-53. PubMed ID: 31873869
[TBL] [Abstract][Full Text] [Related]
40. Discovery of phthalimide derivatives as novel inhibitors of a soluble epoxide hydrolase.
Mahlooji I; Shokri M; Manoochehri R; Mahboubi-Rabbani M; Rezaee E; Tabatabai SA
Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000052. PubMed ID: 32484272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
